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Guest post by Professor Sarah R. Wasserman Rajec*
In Impression Products, Inc. v. Lexmark Inc., decided Tuesday, the
Supreme Court held that the authorized sale of a patented product,
anywhere in the world, exhausts the patentholder’s rights in that
product. The Court overturned Federal Circuit case law holding
that postsale restrictions and foreign sales preserve a U.S. patent
holder’s right to sue for infringement. As a result, Impression
Products was not liable for patent infringement when it bought used
Lexmark toner cartridges abroad from lawful purchasers, refilled
them, and then imported and sold them in the United States, nor did
the postsale restrictions Lexmark placed on its goods give rise to
patent infringement liability. Jason Rantanen has written about the
decision’s impact on postsale use restrictions. I will focus on the
ruling as regards international patent exhaustion.
The decision that an authorized sale anywhere in the world exhausts a
patentee’s rights brings patent law doctrine in line with copyright law
and the Court’s 2013 decision in Kirtsaeng v. John Wiley & Sons, Inc..
In that case, the Court held that textbooks lawfully made and sold in
Thailand could be imported and sold in the United States without
infringing U.S. copyright. Kirtsaeng was not controlling because it
involved statutory interpretation as opposed to the purely doctrinal
nature of exhaustion in patent law, but many of the policy arguments
for copyright apply in the patent context, and many goods are covered
by both types of protection. The greater impact of an international
patent exhaustion rule, as I have previously argued, is that it makes
https://patentlyo.com/patent/2017/06/impressioninternationalexhaustion.html
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U.S. patent law more consistent with free trade principles and is likely
to increase competition by lowering barriers to trade in patented
goods. Companies will no longer be able to use patent rights (without
further strategizing, see below) to engage in geographic price
discrimination between U.S. and foreign markets, and supplychain
participants, resellers, and consumers will not be subject to the
information costs associated with determining the provenance and
travels of all articles of commerce they purchase. These Court makes
clear that the third party benefits that ease the flow of commerce were
important in coming to its decision, colorfully explaining that:
More is at stake when it comes to patents than simply the
dealings between the parties, which can be addressed through
contract law. Instead, exhaustion occurs because, in a sale, the
patentee elects to give up title to an item in exchange for
payment. Allowing patent rights to stick remoralike to that
item as it flows through the market would violate the principle
against restraints on alienation.
Even after looking up “remora,” the opinion leaves open some
questions about international trade in patented goods. Some are legal
and will likely spur further litigation (e.g., whose authorization is
required for an “authorized sale abroad” to occur?) while others are
empirical and still speculative (e.g., with geographic price
discrimination off the table, what other methods will businesses
pursue for price discrimination and control of downstream sales? And,
what will the effect of this ruling be on access to medicine?).
First, the legal question: What is an authorized sale
abroad?
Who needs to authorize the sale? Will companies be able to get around
exhaustion by structuring businesses so that foreign sales are not
authorized by the U.S. patent holder?
In its opinion, the Court stated that “a patentee’s decision to sell a
product exhausts all of its patent rights in that item, regardless of any
restrictions the patentee purports to impose on the location of the
sale.” And, more to the point, “[a]n authorized sale outside the United
States, just as one within the United States, exhausts all rights under
the Patent Act.” However, an authorized sale is not the same as a
lawful sale—it requires an entity capable of authorization in the
United States, and requires that this entity grants authorization in the
foreign market. The Court addressed the issue of what will count as an
authorized sale in its discussion of Boesch v. Graff, an 1890 case in
which the Court ruled that U.S. patent rights were not exhausted by
lawful manufacture and sale in Germany. However, in that case, the
manufacturer was entitled to make and sell the products under a prior
user right in the German patent law which allowed those who were
https://patentlyo.com/patent/2017/06/impressioninternationalexhaustion.html
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preparing to produce a patented article at the time the patent was filed
to do so without authorization. Thus, the Court in Impression
Products explained that Boesch merely illustrates “that a sale abroad
does not exhaust a patentee’s rights when the patentee had nothing to
do with the transaction.”
However, there is a lot of room between Boesch, where the patentee
had “nothing to do with” the manufacture and sales and Impression
Products, where Lexmark had patent rights in multiple countries and
authorized sales abroad. The question remains whether a company
structured such that subsidiaries in different countries own the
various patent rights will be subject to exhaustion of its U.S. patents
for foreign sales made by a foreign subsidiary. The Court seems to
imply not, explaining that “only the patentee can decide whether to
make a sale that exhausts its patent rights in an item,” and later, “what
matters is the patentee’s decision to make a sale.” Yet if it is really the
case that only authorization by the U.S. patentholder will result in
exhaustion through foreign sales, the Court has left open a way for
patent holders to opt out of international exhaustion. And while courts
may interpret “authorized sale” more broadly, to include sales by
related entities, the contours of any rule will take some time to be
settled.
With geographic price discrimination off the table, what
other methods will businesses pursue for price
discrimination and control of downstream sales?
I have previously discussed the economic argument for price
discrimination, explaining that
The standard economic argument against international
exhaustion draws on the potential gains to patent holders and
to consumers in lowincome countries from geographic price
discrimination. This argument describes the current rule as
allowing patent holders to market goods worldwide, adjusting
prices for countries with lower purchasing power while
continuing to reap rewards in highincome countries. An
international exhaustion regime, according to this view, will
push patent holders either to restrict sales to highincome
markets or to offer goods at a globally uniform price, to the
detriment of consumers in lowincome countries. However,
geographical price discrimination is but one of many options
for identifying and marketing to populations with differing
abilities to pay; many goods, regardless of patent protection,
are available in different versions at different prices
worldwide. Geographic price discrimination is desirable to
firms because of its effectiveness at preventing arbitrage and
https://patentlyo.com/patent/2017/06/impressioninternationalexhaustion.html
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because enforcement costs are shared by states through
customs enforcement. It may not be the most desirable form of
price discrimination for consumers, however, because it is
imprecise in identifying differing demand curves. This is
particularly true for countries with large or growing income
disparities. A shift to international exhaustion would likely
result in changes in how firms market goods, but would not
necessarily entail the wholesale welfare losses that the
standard argument suggests, because that argument compares
geographic price discrimination with no price discrimination at
all.
In other words, the useful comparison is not between geographic price
discrimination and no price discrimination, but between geographic
price discrimination and the other methods that companies will
increasingly turn to following this ruling. If instead of choosing not to
sell abroad under the new rule, a company chooses to sell a costly and
a cheaper version of a good, the availability of that cheaper version
may be a boon to consumers inside the United States that otherwise
could not afford the costly version.
Many have suggested that this ruling will lead to more licensing and
fewer sales and I generally agree, where that is technologically
possible and privity can be maintained. However, one thought I’ve had
is that this move towards licensing goods when possible is not isolated
to the patent context in any way. That is, licensing of goods may allow
companies to price discriminate and control (or stop) downstream
sales, and it generally runs counter to the law’s abhorrence for
restraints on alienation, but it was on the rise before this case and
would be just as desirable (to companies and some consumers) or
undesirable (to other consumers and resellers) for goods not covered
by patents as for those that are. So while I agree that we’ll see more
action in this area as a result of the case, and that the dividing line
between licenses and sales is incredibly important to our
understanding of ownership and use of modern and emerging
technologies, it is not an issue of patent law qua patent law.
What will the effect of this ruling be on access to medicine?
International patent exhaustion presents particular concerns for the
advocates of global access to medicines and for the pharmaceutical
industry. Because versioning or licensing do not easily apply to the
sale of drugs, there is a concern that pharmaceutical companies will
refuse to sell medicines at low prices in lowerincome markets because
of a fear of arbitrage. As a result, patients in lowerincome countries
would suffer without access to medicine and pharmaceutical
companies may reap lower profits to invest back into research and
development of new drugs. There are reasons, however, to think that
https://patentlyo.com/patent/2017/06/impressioninternationalexhaustion.html
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the immediate effect on the pharmaceutical industry and patients
worldwide will not and need not be so dire. There are also solid policy
reasons to expand the regulatory means of curbing parallel imports in
this industry.
Currently, the Food & Drug Administration must approve drugs
before they are sold in the United States—both the chemical
composition of the drug and its manufacture. The registration of drugs
and approval of production processes mean that the FDA serves as a
gatekeeper for all who wish to sell drugs in the U.S. market, and an
expansion in this role to exclude drugs first sold in least developed
countries would not exceed the scope of the agency’s current expertise.
And while generally there are good reasons to apply patent law equally
to different technology areas, the drug industry may be appropriate
for special treatment because it is subject to price controls in so many
countries. Thus, while a patentholding pharmaceutical company may
have a choice whether to sell its drug in foreign markets, they have
less control over the price than in the United States, which does not
have a singlepayer system allowing for the strong bargaining power
that many countries have. In addition, because the WTO agreement
on Intellectual Property, the TRIPS Agreement, allows for countries to
issue a compulsory license for patented goods in certain
circumstances, drug companies may face foreign sales that they have
not authorized. Under these circumstances, the free trade concerns
that drive some of the arguments for international exhaustion simply
do not apply in that industry. Combined with the highlyregulated
nature of drug sales in the United States, this provides a strong
argument for treating drugs differently in order to maintain access for
foreign patient populations.
Concluding thoughts
Despite the Court’s suggestion that a rule of international exhaustion
is consistent with prior doctrine, it is a change in the law as
announced by the Federal Circuit and as understood by practitioners
and academics. (The historical claim has been challenged for
both copyrights and patents.) On the domestic side, we can expect to
see even more attempts to structure transactions as licenses rather
than sales, while on the international side, I expect that the question
of patentholder authorization will dominate in the near future.
=====
* Assistant Professor of Law, William & Mary MarshallWythe School
of Law.
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